Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape
- PMID: 35151428
- DOI: 10.1016/j.annonc.2022.01.073
Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape
Conflict of interest statement
Disclosure DIQ reports employment by Abbvie Research and Development and Honoraria for advisory board participation from Merck Sharp and Dohme, Genentech/Roche, Pfizer, EMD Serono, Astellas, Seagen and BMS. AAD, VT and PDZ had no conflicts to report.
Comment on
-
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol. 2022 Mar;33(3):244-258. doi: 10.1016/j.annonc.2021.11.012. Epub 2021 Nov 30. Ann Oncol. 2022. PMID: 34861372 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical